Bacteriophage-based targeting of porphyromonas gingivalis for oral health
Innovative phage-based solution targeting Porphyromonas gingivalis, the oral pathogen linked to periodontal disease, using CRISPR-deficient mutants for precise bacteriophage isolation. This approach aims to reduce pathogenic biofilms while preserving beneficial oral microbes, advancing oral care technology.
Overview
Stella Maris Therapeutics introduces a pioneering bacteriophage-based solution specifically targeting Porphyromonas gingivalis, a primary contributor to periodontal disease and halitosis. By leveraging bacteriophages—viruses that selectively eliminate bacteria—this technology aims to disrupt pathogenic biofilms while maintaining a healthy oral microbiome. This innovative approach addresses the limitations of traditional antiseptics and antibiotics by providing a targeted, microbiome-preserving alternative.
Technical specifications
- Selective Targeting: Utilizes phages for precise elimination of P. gingivalis, minimizing impact on beneficial oral bacteria.
- CRISPR-deficient Mutants: Employs a unique collection of CRISPR-deficient P. gingivalis mutants to facilitate effective phage isolation and selection.
- Biofilm Disruption: Capable of penetrating and disrupting bacterial biofilms associated with chronic periodontal disease.
- Safety Profile: Phages are biologically inert to human cells, ensuring safety for oral applications.
Technology readiness level
Currently at TRL 3, this project is progressing towards TRL 4 with a focused proof-of-concept phase over six months. Initial stages involve optimizing culture conditions and expanding mutant stocks, followed by phage enrichment, screening, and efficacy evaluation. The project aims to deliver decision-enabling data to advance to TRL 5, with potential for further development and product formulation.
About Stella Maris Therapeutics
Stella Maris Therapeutics is a biotechnology-focused company that develops and provides butyrate supplements to support gut and brain health. The company utilizes scientific research on the gut-brain axis to create innovative postbiotic solutions. Its flagship product is a high-quality, sodium-based butyrate supplement formulated with a specialized encapsulation strategy, using cellulose and gellan gum to ensure the compound reaches the colon, where it can be effectively utilized by intestinal cells to strengthen the gut barrier and reduce inflammation.
Founded by Dr. Daniel Czyz, an associate professor who studies microbial pathogenesis and neurodegenerative diseases, the company focuses on improving outcomes for individuals dealing with chronic inflammatory and neurodegenerative conditions, including Parkinson’s disease, inflammatory bowel disease, and rheumatoid arthritis. By combining rigorous quality control with a commitment to building relationships with patients and customers, Stella Maris Therapeutics aims to offer evidence-based wellness solutions that address the communication between the digestive system and the nervous system.
Inquire about this partnering listing
Looking for
Industry applications
delivered to your inbox.